Provera Articles
Pfizer fights back on HRT and cancer links highlighted by NYT
14 December 2009
$27M damages thrown out for Wyeth/Upjohn
21 July 2008
Danger to patients from weak US Rx system: CU
12 December 2005
Survey shows women not choosing most effective contraceptives
24 October 2001
Ligand gets $900K payment as lasofoxifene enters Ph III
27 September 2000
California Row Over Contraceptive Cover
11 February 1998
Pharmacia & Upjohn First Combined Results
26 February 1996
Upjohn suing AHP for infringment on Provera
22 May 1995
Two More Launches For Upjohn's Freedox
24 April 1995
Depo-Provera Not Indicated In Breast Cancer
17 April 1995
End Of Year Encouraging For US Companies
6 February 1995
Norplant Lawsuit To Expand Focus
18 July 1994
UPJOHN OUTLINES STRATEGIC DIRECTIONS
18 April 1994
US CONTRACEPTIVE PRICING SLAMMED
28 March 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
UPJOHN AGREEMENT
25 October 1993
WHO APPROVES SHORT-TERM CONTRACEPTION INJECTION
28 June 1993
DEPO-PROVERA SLATED IN CANADA
14 June 1993
DEPO PROVERA GOAHEAD FROM WHO
7 June 1993
WYETH-AYERST WIDENS GENERIC LINE
17 May 1993
DEPO-PROVERA US APPROVAL WELCOMED
9 November 1992
NEW YORK STOCK COMMENT
3 August 1992
SHIFTS FORECAST IN US CONTRACEPTIVES MARKET
3 August 1992
UPJOHN REVISES EARNINGS OUTLOOK
29 June 1992
WILL DEPO-PROVERA EVER APPEAR IN USA?
29 June 1992
UPJOHN RESUBMITS DEPO-PROVERA IN USA
15 June 1992
FREEZES AT UPJOHN IN STRATEGY REVIEW
8 June 1992
HORMONE REPLACEMENT THERAPY: US REPORT
8 June 1992
Showing 1-28 of 28 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
